Complaint Investigation Report

Both bottles had a quantity of 60 pills per the prescription labels opened on January 21, 2024. LPA reviewed and counted the remaining tablets twice. There were 13 tablets remaining for the Sprinolactone 100mg and 14 tablets remaining for the Spironolactone 50mg. It was documented on the MAR that R1 received both medications daily in February and March 2024 even though the 100mg bottle had one less tablet. Neither MAR nor the Med Pass Exceptions did not indicate that the medications were refused or not taken from January to March 2024 which corroborates facility failed to properly manage the medications.

Therefore, the preponderance of evidence standard has been met. A deficiency is being cited on the attached LIC9099-D.

An exit interview was conducted with Executive Director Kyle Coleman, and a copy of this report including the appeal rights were provided at the end of the visit.